Bristol-Myers Squibb Company (BMY)

$43.83 0.00 (N/A)
Market Cap 89.21B
Revenue (ttm) 48.30B
Net Income (ttm) -8.95B
EPS (ttm) N/A
PE Ratio 6.60
Forward PE 6.95
Profit Margin -18.53%
Debt to Equity Ratio 2.81
Volume 10,105,800
Avg Vol 14,111,561
Day's Range N/A - N/A
Shares Out 2.04B
Stochastic %K 34%
Beta 0.33
Analysts Sell
Price Target $52.68

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 609 252 4621
Website: www.bms.com
Address:
Route 206 & Province Line Road, Princeton, United States
SuperGreenToday
SuperGreenToday Oct. 25 at 12:34 AM
$BMY Share Price: $43.84 Contract Selected: Nov 21, 2025 $45 Calls Buy Zone: $1.14 – $1.41 Target Zone: $2.08 – $2.54 Potential Upside: 72% ROI Time to Expiration: 27 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 11:47 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BMY Current Share Price: $43.79 Contracts: $BMY December 18, 2026 $45 Calls Scale in: $4.41- $5.39 Scale out: $6.86-$8.82 Can Easily Capture: 60% ROI Blended DTE: 421 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Investment8844
Investment8844 Oct. 24 at 8:37 PM
$BMY Are we gonna see $50+ post ER ? Or we gonna see $36 finally again?
1 · Reply
Tuttaz
Tuttaz Oct. 24 at 8:01 PM
$BMY Should be 65+...
0 · Reply
stocksuck
stocksuck Oct. 24 at 7:18 PM
$BMY market new high and this down again what a piece of shit
0 · Reply
stocksuck
stocksuck Oct. 24 at 5:50 PM
$BMY I bought another 100 shares
0 · Reply
cb5000calls
cb5000calls Oct. 24 at 2:36 PM
$SLS This is a cornerstone IP filing — not a generic chemistry patent but a precision-medicine lock around ASXL1-mutated cancers. It secures Sellas’ differentiation in AML and MDS and supports expansion into solid tumors (colorectal, liver, breast). The inclusion of venetoclax + azacitidine combinations directly positions this as first-line-compatible with current AML standards. Expect this to be a core due-diligence element if any large pharma (e.g., $ABBV , $BMY , $PFE ) considers acquisition or co-development. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2025217597
2 · Reply
taxplanr
taxplanr Oct. 24 at 2:31 PM
Using the bodies own mitochondria to combat cancers chronic illnesses and autoimmune diseases is what emf device companies like $ECOR can do Not failed malignantRNA platforms with toxic chemo does $BNTX $MRNA $BMY
0 · Reply
stocksuck
stocksuck Oct. 24 at 1:35 PM
$BMY will stock ever go up
1 · Reply
Fredsavage911
Fredsavage911 Oct. 24 at 1:31 PM
$BMY
0 · Reply
Latest News on BMY
Buy 9 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 October Dividend Dogs

Oct 24, 2025, 7:54 AM EDT - 1 day ago

Buy 9 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 October Dividend Dogs

BBB CAG EQR KEY KIM LYB MO

Bristol-Myers Squibb: This High FCF Yield Is The Best Value In Healthcare

Oct 23, 2025, 5:20 PM EDT - 1 day ago

Bristol-Myers Squibb: This High FCF Yield Is The Best Value In Healthcare

These low-risk stocks could be a profitable answer to this volatile earnings season

Oct 23, 2025, 10:52 AM EDT - 1 day ago

These low-risk stocks could be a profitable answer to this volatile earnings season

AMGN CVS GD GIS HQY HRL JNJ

The Play On Bristol-Myers Squibb

Oct 21, 2025, 11:27 AM EDT - 3 days ago

The Play On Bristol-Myers Squibb

My Top 3 Pharma Stocks

Oct 20, 2025, 11:38 AM EDT - 4 days ago

My Top 3 Pharma Stocks

AKRO ETNB LLY MRK NVO PFE SPY

October's 5 Dividend Growth Stocks With Yields Up To 8.33%

Oct 20, 2025, 11:34 AM EDT - 4 days ago

October's 5 Dividend Growth Stocks With Yields Up To 8.33%

IYR MO RLJ UPS VICI XLV

Undercovered Dozen: NANO Nuclear Energy, Zeta Global, Blue Owl And More

Oct 17, 2025, 10:17 AM EDT - 7 days ago

Undercovered Dozen: NANO Nuclear Energy, Zeta Global, Blue Owl And More

NNE ZETA CSWC ENVX ET HTGC JPM

SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025

Oct 17, 2025, 10:00 AM EDT - 7 days ago

SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields

Oct 15, 2025, 7:15 AM EDT - 10 days ago

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields

PFE PRGO

Final Trade: WMT, AMZN, F, BMY

Oct 14, 2025, 6:20 PM EDT - 10 days ago

Final Trade: WMT, AMZN, F, BMY

AMZN WMT F

Stock Looks Undervalued As Bristol Myers Buys Orbital Therapeutics

Oct 13, 2025, 7:30 AM EDT - 12 days ago

Stock Looks Undervalued As Bristol Myers Buys Orbital Therapeutics

Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types

Oct 13, 2025, 6:59 AM EDT - 12 days ago

Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types

SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration

Oct 13, 2025, 5:00 AM EDT - 12 days ago

SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration

Buy Any Of 14 IDEAL 'Safer' S&P 500 October Dividend Dogs

Oct 12, 2025, 10:11 AM EDT - 12 days ago

Buy Any Of 14 IDEAL 'Safer' S&P 500 October Dividend Dogs

AES AMCR ARE CAG CPB DOC DOW

Bristol Myers Squibb: Value Emerges From Distress

Oct 11, 2025, 9:52 AM EDT - 13 days ago

Bristol Myers Squibb: Value Emerges From Distress

Bristol Myers buys Orbital Therapeutics for $1.5 billion

Oct 10, 2025, 7:05 AM EDT - 15 days ago

Bristol Myers buys Orbital Therapeutics for $1.5 billion

Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics

Oct 10, 2025, 6:59 AM EDT - 15 days ago

Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics

Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection

Oct 10, 2025, 6:45 AM EDT - 15 days ago

Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection

Bristol-Myers Squibb: Your Chance To Buy A Bargain 6% Yield

Oct 9, 2025, 12:00 PM EDT - 15 days ago

Bristol-Myers Squibb: Your Chance To Buy A Bargain 6% Yield

My Top 5 Biotech Stocks Big Pharma Could Buy Next

Oct 6, 2025, 1:29 PM EDT - 18 days ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BIIB GILD

Final Trade: GDX, PFE, GFS, BMY

Oct 1, 2025, 6:32 PM EDT - 23 days ago

Final Trade: GDX, PFE, GFS, BMY

GDX GFS PFE

‘Fast Money' traders talk opportunities in health care stocks

Oct 1, 2025, 5:48 PM EDT - 23 days ago

‘Fast Money' traders talk opportunities in health care stocks

AMGN BIIB IBB LLY MRK MRNA PFE

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

Oct 1, 2025, 7:58 AM EDT - 24 days ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

GSK XRAY

Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease

Oct 1, 2025, 6:59 AM EDT - 24 days ago

Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease

Bristol Myers, Takeda to pool data for AI-based drug discovery

Oct 1, 2025, 5:31 AM EDT - 24 days ago

Bristol Myers, Takeda to pool data for AI-based drug discovery

TAK

7 Ideal "Safer" Dividend Buys From 61 September Graham Value All-Stars (GVAS)

Sep 30, 2025, 12:16 PM EDT - 24 days ago

7 Ideal "Safer" Dividend Buys From 61 September Graham Value All-Stars (GVAS)

BBVA CMCSA E EPD ET MFC MO

Buy 7 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 September Dividend Dogs

Sep 28, 2025, 10:10 AM EDT - 26 days ago

Buy 7 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 September Dividend Dogs

BBY CAG EQR KEY KIM KMI LYB

Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access

Sep 26, 2025, 12:21 PM EDT - 4 weeks ago

Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access

ABBV LLY MRK PFE BIIB

Bristol Myers to sell psoriasis drug at over 80% discount

Sep 25, 2025, 7:08 AM EDT - 4 weeks ago

Bristol Myers to sell psoriasis drug at over 80% discount

Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)

Sep 25, 2025, 6:59 AM EDT - 4 weeks ago

Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)

Bristol-Myers Squibb Company (BMY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript

Sep 23, 2025, 1:13 PM EDT - 4 weeks ago

Bristol-Myers Squibb Company (BMY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript

Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma

Sep 23, 2025, 6:59 AM EDT - 4 weeks ago

Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma

Buy Bristol Myers Squibb Stock At $45?

Sep 23, 2025, 6:55 AM EDT - 4 weeks ago

Buy Bristol Myers Squibb Stock At $45?

Bristol Myers plans to launch schizophrenia drug in UK at list price equal to the US

Sep 22, 2025, 7:26 AM EDT - 4 weeks ago

Bristol Myers plans to launch schizophrenia drug in UK at list price equal to the US

Bristol Myers Squibb: Buy This Deep Bargain Before The Market Wakes To Income

Sep 20, 2025, 8:30 AM EDT - 4 weeks ago

Bristol Myers Squibb: Buy This Deep Bargain Before The Market Wakes To Income

Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025

Sep 19, 2025, 6:59 AM EDT - 5 weeks ago

Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025

Dividend Harvesting Portfolio Week 237: $23,700 Allocated, $2,573.68 In Projected Dividends

Sep 18, 2025, 8:45 AM EDT - 5 weeks ago

Dividend Harvesting Portfolio Week 237: $23,700 Allocated, $2,573.68 In Projected Dividends

ENB MO NNN SLG

J&J's experimental psoriasis drug shows promise against Bristol's treatment

Sep 17, 2025, 8:27 AM EDT - 5 weeks ago

J&J's experimental psoriasis drug shows promise against Bristol's treatment

JNJ

Bristol Myers Squibb Announces Dividend

Sep 17, 2025, 6:59 AM EDT - 5 weeks ago

Bristol Myers Squibb Announces Dividend

Bristol Myers to sell 60% stake in China joint venture

Sep 17, 2025, 12:04 AM EDT - 5 weeks ago

Bristol Myers to sell 60% stake in China joint venture

10 Quality High Yield In Rose's Income Garden Portfolio: 5 Winners To Buy

Sep 16, 2025, 10:46 AM EDT - 5 weeks ago

10 Quality High Yield In Rose's Income Garden Portfolio: 5 Winners To Buy

AES ARE BTI CVX MO NNN VZ

These stock-market experts don't love AI. Here's what they do recommend.

Sep 16, 2025, 7:30 AM EDT - 5 weeks ago

These stock-market experts don't love AI. Here's what they do recommend.

NVDA

Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

Sep 16, 2025, 6:59 AM EDT - 5 weeks ago

Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

Meet 16 Ideal "Safer" September Dividend Dogs Of The S&P500

Sep 12, 2025, 3:12 PM EDT - 6 weeks ago

Meet 16 Ideal "Safer" September Dividend Dogs Of The S&P500

AMCR ARE CAG CPB D DOC DOW

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

Sep 8, 2025, 2:01 PM EDT - 6 weeks ago

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

BNTX

Bristol-Myers Squibb Company (BMY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 12:15 PM EDT - 6 weeks ago

Bristol-Myers Squibb Company (BMY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

Sep 8, 2025, 11:05 AM EDT - 6 weeks ago

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

BNTX

Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point

Sep 8, 2025, 9:47 AM EDT - 6 weeks ago

Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point

Bristol-Myers Squibb: Growth Portfolio Surpasses Legacy, Driving Oncology And Immunology Leadership

Sep 7, 2025, 9:47 AM EDT - 6 weeks ago

Bristol-Myers Squibb: Growth Portfolio Surpasses Legacy, Driving Oncology And Immunology Leadership

Bristol Myers Squibb: A 5% Yield And Single-Digit P/E Still Look Good

Sep 6, 2025, 7:15 AM EDT - 7 weeks ago

Bristol Myers Squibb: A 5% Yield And Single-Digit P/E Still Look Good

SuperGreenToday
SuperGreenToday Oct. 25 at 12:34 AM
$BMY Share Price: $43.84 Contract Selected: Nov 21, 2025 $45 Calls Buy Zone: $1.14 – $1.41 Target Zone: $2.08 – $2.54 Potential Upside: 72% ROI Time to Expiration: 27 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 11:47 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BMY Current Share Price: $43.79 Contracts: $BMY December 18, 2026 $45 Calls Scale in: $4.41- $5.39 Scale out: $6.86-$8.82 Can Easily Capture: 60% ROI Blended DTE: 421 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Investment8844
Investment8844 Oct. 24 at 8:37 PM
$BMY Are we gonna see $50+ post ER ? Or we gonna see $36 finally again?
1 · Reply
Tuttaz
Tuttaz Oct. 24 at 8:01 PM
$BMY Should be 65+...
0 · Reply
stocksuck
stocksuck Oct. 24 at 7:18 PM
$BMY market new high and this down again what a piece of shit
0 · Reply
stocksuck
stocksuck Oct. 24 at 5:50 PM
$BMY I bought another 100 shares
0 · Reply
cb5000calls
cb5000calls Oct. 24 at 2:36 PM
$SLS This is a cornerstone IP filing — not a generic chemistry patent but a precision-medicine lock around ASXL1-mutated cancers. It secures Sellas’ differentiation in AML and MDS and supports expansion into solid tumors (colorectal, liver, breast). The inclusion of venetoclax + azacitidine combinations directly positions this as first-line-compatible with current AML standards. Expect this to be a core due-diligence element if any large pharma (e.g., $ABBV , $BMY , $PFE ) considers acquisition or co-development. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2025217597
2 · Reply
taxplanr
taxplanr Oct. 24 at 2:31 PM
Using the bodies own mitochondria to combat cancers chronic illnesses and autoimmune diseases is what emf device companies like $ECOR can do Not failed malignantRNA platforms with toxic chemo does $BNTX $MRNA $BMY
0 · Reply
stocksuck
stocksuck Oct. 24 at 1:35 PM
$BMY will stock ever go up
1 · Reply
Fredsavage911
Fredsavage911 Oct. 24 at 1:31 PM
$BMY
0 · Reply
taxplanr
taxplanr Oct. 23 at 7:56 PM
$MRK $BMY EMF feeds and energizes Mitochondria not destroy it like malignantRNA
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 23 at 5:12 PM
Enter: $BMY NOV 14 2025 $45 CALLS Buy in Price: $1.76 - $1.85 Take Profit: $3.38 Stop Bleeding: $1.55 ROI Potential: 92% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
Midas8888
Midas8888 Oct. 23 at 3:16 PM
$ADAP $BMY $HCA $
0 · Reply
framus_morrigan
framus_morrigan Oct. 23 at 2:51 PM
$BMY I hate this name ... >_<
1 · Reply
Midas8888
Midas8888 Oct. 23 at 2:39 PM
$ADAP $BMY $HCA
0 · Reply
Lincoln_Osiris
Lincoln_Osiris Oct. 23 at 2:32 PM
$BMY Best buy in the market for an easy 20-25% return in a year with capital appreciation, dividend, and OTM covered calls.
1 · Reply
Fredsavage911
Fredsavage911 Oct. 23 at 12:59 PM
$BMY Leronlimab (LL) a CCR5 inhibitor from Cytodyn (Cydy) was used in combination with checkpoint for hibitors in patients with metastatic triple negative breast cancer. LL increased PDL-1 allowing ICI to work in patients with previously cold tumors (tumors lacking PD-1/PDL-1). Below are initial results.
1 · Reply
biolover
biolover Oct. 23 at 12:08 PM
$TNGX $TNGX data out. Secures private funding for phase 3 Tolerability looks BIC Impressive RR in histology agnostic MTAP deleted tumors Overall RR 27%. ( $BMY reported 21%. ) BMS drug had some dose limiting toxicities of seizure and GI. Which is not seen with tango. There was mild liver enzyme, elevation with BMY which could complicate combinations and this is not seeing with Tango drug 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% – – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 – – 49% ORR and mPFS 9.1 months in histology agnostic cohort of multiple late line, difficult to treat cancers provide further evidence of strong activity –
0 · Reply
Quantumup
Quantumup Oct. 23 at 11:30 AM
JPMorgan⬆️the PT on $IDYA to $79 from $74, reiterated at an Overweight, and⬆️ darovasertib's probability of success (PoS) in the neoadjuvant setting to 70% from 60%—estimates peak sales of $500M in the U.S. alone—sees share upside into the mUM update. $IMCR $PFE $MRK $BMY
0 · Reply
Stonkadonkera
Stonkadonkera Oct. 23 at 3:10 AM
$SLS not selling til $BMY or $PFE open the vault that $SLS can back the truck up to.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 23 at 12:30 AM
Enter: $BMY NOV 14 2025 $45 CALLS Buy in Price: $1.76 - $1.92 Take Profit: $3.91 Stop Bleeding: $1.55 ROI Potential: 122% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
taxplanr
taxplanr Oct. 22 at 9:43 PM
$BNTX same old story for malignantRNA platform $BMY
0 · Reply